Clinical Research

CIRCULARITY-FUNDED RESEARCH
PERFORMED BY HEALTHCARE EXPERTS

Title: New prospect of treatment of wound healing

  • Researcher: Professor Puruhito
    o Thoracic, cardiac and vascular surgery, medical faculty, Universitas Airlangga, Surabaya, Indonesia
  • Sample: Diabetic patients with ulcers identified as Wagner 1 to 3.

Most important findings:

  • All diabetic foot ulcers evaluated during the study time period presented marked clinical improvements, and some patients gained total ulcer resolution.

Title: Complex treatment of complicated crural decollement injury in a diabetic patient

  • Researchers: I. Gárgyán, Á. Csonka, K. Boa, E. Varga
    o Department of Traumatology, University of Szeged, Hungary
  • Sample: Case presentation

Most important findings:

  • A patient had a stage 4 ulcer with necrotic borders secondary to a car-accident-associated fracture with massive soft tissue contusion and crural decollement. Results: The physician used the D’OXYVA® medical device as adjuvant therapy to save the patient’s limb from amputation and obtain complete ulcer resolution after 3 months of therapy.

Title: Transdermal delivery of carbon dioxide boosts microcirculation in subjects with and without diabetes

Researchers: Lee C. Rogers, D.P.M., Judy M. Muller-Delp, Ph.D., Topy A. Mudde, MSc.

  • Sample: Healthy and diabetic patients

Most important findings:

  • All of the flux parameters demonstrated marked improvement after the use of the D’OXYVA® device. The skin perfusion index increased after COtransdermal treatment. The diabetic participants demonstrated the most flux improvement after treatment, compared with healthy individuals. Both groups demonstrated improved blood pressure.

Title: Pilot study of D’OXYVA® transdermal gas delivery device in adult equines

Researchers: Dr. Karen Indreland, DVM

Sample: Healthy horses

Most important findings:

A D’OXYVA® device was used to provide high-concentration-COwater vapor, which increased microcirculation (flux) blood flow in the superficial skeletal muscle and skin of equines, compared with the control group.

Why can the D’OXYVA®  medical device and its capacity to produce highly concentrated COvapor improve general health care?

Judy M. Delp, Ph.D. professor of Biomedical Sciences in physiology and professor at the Florida State University, described D’OXYVA® as a simple commercially available device used to deliver transdermal CO2that has shown remote vasodilation, which may be mediated through the release of a circulating humoral agent.** COimproves general healthcare in several ways:
      • It has natural anti-inflammatory characteristics.
      • It increases blood flow through microcirculation, by arteriolar/venous dilatation.
      • It produces a rightward shift in the Odissociation curve.
      • It enhances oxygen delivery at the cellular level in the muscles, organs, brain, skin and other parts of the body.
      • It is a fat-dissolving compound.
      • It naturally sedates and calms the central nervous system.
      • It can be used to reconstruct functionally closed capillaries.
      • It can improve venous response.
      • It improves blood-flow properties.
      • It can be used to sedate the central nervous system.
**Individual results may vary. Ask your doctor before taking D’OXYVA. For prescription for medical use. Read D’OXYVA Regulatory Statements >

Fill out the form below to download a FREE copy of D'OXYVA's outstanding clinical research results!